Related Experiment Video
Updated: May 24, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
VIPER-TACs leverage viral E3 ligases for disease-specific targeted protein degradation
Kyle Mangano1, Robert G Guenette2, Spencer Hill2
1Induced Proximity Platform, Amgen Research, Thousand Oaks, CA 91320, USA; Amgen R&D Postdoctoral Fellows Program, Thousand Oaks, CA 91320, USA.
Abstract:
In targeted protein degradation (TPD) a protein of interest is degraded by chemically induced proximity to an E3 ubiquitin ligase. One limitation of using TPD therapeutically is that most E3 ligases have broad tissue expression, which can contribute to toxicity via target degradation in healthy cells. Many pathogenic and oncogenic viruses encode E3 ligases (vE3s), which de facto have strictly limited expression to diseased cells. Here, we provide proof-of-concept for viral E3 pan-essential removing targeting chimeras (VIPER-TACs) that are bi-functional molecules that utilize viral E3 ubiquitin ligases to selectively degrade pan-essential proteins and eliminate diseased cells. We find that the human papillomavirus (HPV) ligase E6 can degrade the SARS1 pan-essential target protein in a model of HPV-positive cervical cancer to selectively kill E6 expressing cancer cells. Thus, VIPER-TACs have the capacity to dramatically increase the therapeutic window, alleviate toxicity concerns, and ultimately expand the potential target space for TPD.
Insights
Viral E3 ligases offer targeted protein degradation in diseased cells. Viral E3 pan-essential removing targeting chimeras (VIPER-TACs) selectively degrade proteins, enhancing therapeutic windows and reducing toxicity.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Targeted protein degradation (TPD) uses E3 ubiquitin ligases to degrade proteins.
- Current TPD therapies face toxicity due to broad E3 ligase expression in healthy tissues.
- Viral E3 ligases (vE3s) are expressed only in diseased cells, offering a potential solution.
Purpose of the Study:
- To introduce viral E3 pan-essential removing targeting chimeras (VIPER-TACs) as a novel therapeutic strategy.
- To demonstrate the selective degradation of essential proteins in diseased cells using VIPER-TACs.
- To explore the potential of VIPER-TACs in cancer therapy.
Main Methods:
- Development of bi-functional VIPER-TAC molecules.
- Utilizing human papillomavirus (HPV) E6 ligase as a vE3.
- Testing VIPER-TACs in a model of HPV-positive cervical cancer targeting a pan-essential protein.
Main Results:
- Proof-of-concept for VIPER-TACs achieved.
- HPV E6 ligase successfully degraded a pan-essential target protein.
- Selective killing of E6-expressing cancer cells demonstrated.
Conclusions:
- VIPER-TACs selectively degrade essential proteins in diseased cells.
- This approach significantly increases the therapeutic window and reduces toxicity.
- VIPER-TACs expand the potential applications of TPD in cancer treatment.
More Related Videos
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Tagging and Fusion Proteins
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...

